Related Experiment Video
Updated: May 27, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Philip Barter1, Kerry-Anne Rye
1The Heart Research Institute, 7 Eliza Street, Newtown, Sydney 2042, Australia. barterp@hri.org.au
Insights
Cholesteryl ester transfer protein (CETP) inhibitors aim to raise HDL-C for cardiovascular disease prevention. Newer CETP inhibitors are being tested in clinical trials to re-evaluate their efficacy and safety.
Area of Science:
- Cardiovascular medicine
- Pharmacology
- Lipid metabolism
Background:
- Elevated low-density lipoprotein-cholesterol (LDL-C) and reduced high-density lipoprotein-cholesterol (HDL-C) are key risk factors for cardiovascular disease (CVD).
- Cholesteryl ester transfer protein (CETP) facilitates the transfer of cholesteryl esters from HDL to other lipoproteins, influencing lipid profiles.
- Inhibiting CETP is a strategy to increase HDL-C levels and potentially reduce CVD risk.
Purpose of the Study:
- To re-evaluate the anti-atherogenic potential of CETP inhibitors.
- To assess the safety and efficacy of CETP inhibitors that lack the adverse off-target effects of earlier agents like torcetrapib.
Main Methods:
- Clinical outcome trials are underway with novel CETP inhibitors, specifically dalcetrapib and anacetrapib.
- These trials aim to determine if CETP inhibition, without torcetrapib's off-target effects, proves beneficial in preventing cardiovascular events.
Main Results:
- Previous CETP inhibitor torcetrapib was associated with increased mortality and cardiovascular events, possibly due to off-target effects.
- Current trials with dalcetrapib and anacetrapib are designed to isolate the effects of CETP inhibition itself.
Conclusions:
- The hypothesis that CETP inhibitors are anti-atherogenic is being re-examined with newer agents.
- Ongoing clinical trials will provide crucial data on the cardiovascular benefits and risks of selective CETP inhibition.
Abstract:
Elevated low-density lipoprotein-cholesterol (LDL-C) and reduced high-density lipoprotein-cholesterol (HDL-C) are major risk factors for the development of cardiovascular disease. One approach to raising HDL-C is to inhibit the cholesteryl ester transfer protein (CETP), a plasma protein that promotes transfer of cholesteryl esters from HDL and other lipoprotein fractions. Drugs that inhibit CETP increase HDL-C and some lower LDL-C. However, the development of torcetrapib, the first CETP inhibitor to be tested in a human clinical outcomes trial, was terminated because it caused an excess of deaths and cardiovascular events. There is evidence, however, that torcetrapib had adverse off-target effects unrelated to CETP inhibition. This has opened the way for retesting of the hypothesis that CETP inhibitors will be anti-atherogenic in studies conducted with agents such as dalcetrapib and anacetrapib that do not share the off-target effects of torcetrapib. Clinical outcome trials with dalcetrapib and anacetrapib are currently under way.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
